Article

Reporter-Based Isolation of Induced Pluripotent Stem Cell- and Embryonic Stem Cell-Derived Cardiac Progenitors Reveals Limited Gene Expression Variance

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, 94158, USA.
Circulation Research (Impact Factor: 11.09). 08/2010; 107(3):340-7. DOI: 10.1161/CIRCRESAHA.109.215434
Source: PubMed

ABSTRACT Induced pluripotent stem (iPS) cells can differentiate into multiple cell types, including cardiomyocytes and have tremendous potential for drug discovery and regenerative therapies. However, it is unknown how much variability exists between differentiated lineages from independent iPS cell lines and, specifically, how similar iPS cell-derived cardiomyocytes (iPS-CMs) are to embryonic stem (ES) cell-derived cardiomyocytes (ES-CMs).
We investigated how much variability exists between differentiated lineages from independent iPS cell lines and how similar iPS-CMs are to ES-CMs.
We generated mouse iPS cells in which expression of NKX2-5, an early cardiac transcription factor, was marked by transgenic green fluorescent protein (GFP). Isolation of iPS- and ES-derived NKX2-5-GFP(+) cardiac progenitor pools, marked by identical reporters, revealed unexpectedly high similarity in genome-wide mRNA expression levels. Furthermore, the variability between cardiac progenitors derived from independent iPS lines was minimal. The NKX2-5-GFP(+) iPS cells formed cardiomyocytes by numerous induction protocols and could survive upon transplantation into the infarcted mouse heart without formation of teratomas.
Despite the line-to-line variability of gene expression in the undifferentiated state of ES and iPS cells, the variance narrows significantly in lineage-specific iPS-derived cardiac progenitors, and these progenitor cells can be isolated and used for transplantation without generation of unwanted cell types.

Full-text

Available from: Bruce Conklin, Mar 26, 2014
0 Followers
 · 
154 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myocardial cell-replacement therapies are emerging as novel therapeutic paradigms for myocardial repair but are hampered by the lack of sources of autologous human cardiomyocytes. The recent advances in stem cell biology and in transcription factor-based reprogramming strategies may provide exciting solutions to this problem. In the current review, we describe the different reprogramming strategies that can give rise to cardiomyocytes for regenerative medicine purposes. Initially, we describe induced pluripotent stem cell technology, a method by which adult somatic cells can be reprogrammed to yield pluripotent stem cells that could later be coaxed ex vivo to differentiate into cardiomyocytes. The generated induced pluripotent stem cell-derived cardiomyocytes could then be used for myocardial cell transplantation and tissue engineering strategies. We also describe the more recent direct reprogramming approaches that aim to directly convert the phenotype of one mature cell type (fibroblast) to another (cardiomyocyte) without going through a pluripotent intermediate cell type. The advantages and shortcomings of each strategy for cardiac regeneration are discussed, along with the hurdles that need to be overcome on the road to clinical translation.
    STEM CELLS TRANSLATIONAL MEDICINE 03/2014; DOI:10.5966/sctm.2013-0163 · 3.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart disease is the leading cause of death in the world and is likely to remain as such in the foreseeable future. There is a great deal of optimism for cardiac regenerative therapies because recent advances in stem cell technology have made it possible to derive millions of cardiomyocytes from human embryonic stem cells and induced pluripotent stem cells. These stem cell-derived cardiac cells also have an enormous potential in drug discovery, toxicology studies and fundamental cardiac physiology. Cardiomyocytes do not have well-established, specific surface markers to enable their separation from heterogeneous cultures using transient antibody labelling and traditional methods such as fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS). Therefore, a major obstacle in realizing their potential is the development of separation methods that are compatible with clinical applications and can isolate cardiomyocytes and specific cardiac cell subpopulations after in vitro culture in sufficient numbers, purity and quality. This review provides an overview of the present state of the art in labelled and label-free cardiomyocyte isolation, the challenges to the field and a perspective on the future of cardiac cell separation.
    11/2014; 4(11):845-867. DOI:10.1166/jbt.2014.1270
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The demonstration of beneficial effects of cell therapy despite the persistence of only few transplanted cells in vivo suggests secreted factors may be the active component of this treatment. This so-called paracrine hypothesis is supported by observations that culture media conditioned by progenitor cells contain growth factors that mediate proangiogenic and cytoprotective effects. Cardiac progenitor cells in semi-suspension culture form spherical clusters (cardiospheres) that deliver paracrine signals to neighboring cells. A key component of paracrine secretion is exosomes, membrane vesicles that are stored intracellularly in endosomal compartments and are secreted when these structures fuse with the cell plasma membrane. Exosomes have been identified as the active component of proangiogenic effects of bone marrow CD34(+) stem cells in mice and the regenerative effects of embryonic mesenchymal stem cells in infarcted hearts in pigs and mice. Here, we provide electron microscopic evidence of exosome secretion by progenitor cells in mouse myocardium and human cardiospheres. Exosomes are emerging as an attractive vector of paracrine signals delivered by progenitor cells. They can be stored as an "off-the-shelf" product. As such, exosomes have the potential for circumventing many of the limitations of viable cells for therapeutic applications in regenerative medicine.
    BioMed Research International 11/2012; 2012:354605. DOI:10.1155/2012/354605 · 2.71 Impact Factor